Lack of an association of estrogen receptor α gene polymorphisms and transcriptional activity with Alzheimer disease

Archives of Neurology

Volumn 57, Issue 2, 2000, Pages 236-240

  Maruyama, Hirofumi ^a   Toji, Hiromasa ^a   Harrington, Charles R ^b   Sasaki, Ken ^c   Izumi, Yuishin ^a   Ohnuma, Tohru ^d   Arai, Heii ^d   Yasuda, Minoru ^e   Tanaka, Chikako ^e   Emson, Piers C ^f   Nakamura, Shigenobu ^a   Kawakami, Hideshi ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Kinoko Espoir Hospital   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e Hyogo Inst Aging Brain Cogn D   (Japan)

^f BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LUCIFERASE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; ENHANCER REGION; EXON; FEMALE; GENETIC TRANSCRIPTION; HUMAN; INTRON; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN METABOLISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 12944260636     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.2.236     Document Type: Article

References (37)

1. Saunders AM, Strittmatter WJ. Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
2. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.
3. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122-126.
4. Gibbs RB, Hashash A, Johnson DA. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Brain Res. 1997;749:143-146.
5. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter G. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
6. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996;46:1580-1584.
7. Smalheiser NR, Swanson DR. Linking estrogen to Alzheimer's disease: an informatic approach. Neurology. 1996;47:809-810.
8. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease Lancet. 1996;348:429-432.
9. Lerner A, Koss E, Debanne S, Rowland D, Smyth K, Friedland R. Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease. Lancet. 1997;349:403-404.
10. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology. 1997;48:1517-1521.
11. Baldereschi M, Carlo AD, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the italian longitudinal study on aging. Neurology. 1998;50: 996-1002.
12. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.
13. Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
14. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem. 1994;269: 13065-13068.
15. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology. 1997;48(suppl 7):S36-S41.
16. Hill SM, Fuqua SAW, Chamnee GC, Greene GL, McGuire WL. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989;49:145-148.
17. Lehrer S, Sanchez M, Song HK, et al. Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet. 1990; 335:622-624.
18. Lehrer S, Rabin J, Kalir T. Schachter BS. Estrogen receptor variant and hypertension in women. Hypertension. 1993;21:439-441.
19. Sano M, Inoue S, Hosoi T, et al. Association of estrogen receptor dinucleotide repeat polymorphism withosteoporosis. Biochem Biophys Res Commun. 1995; 217:378-383.
20. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res. 1996;11:306-311.
21. Isoe K, Ji Y, Urakami K, Adachi Y, Nakashima K. Genetic association of estrogen receptor gene polymorphisms with Alzheimer's disease. Alzheimer's Res. 1997; 3:195-197.
22. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Am J Pathol. 1994;145:1472-1484.
23. De Wet JR, Wood KV, Helinski DR, Deluca M. Cloning of firefly luciferase cDNA and the expression of active luciferase in Escherichia coli. Proc Natl Acad Sci U S A. 1985;82:7870-7873.
24. Lorenz WW, McCann RO, Longiaru M, Cormier MJ. Isolation and expression of a cDNA encoding Renilla reniformis luciferase. Proc Natl Acad Sci U S A. 1991; 88:4438-4442.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
26. Tang MX, Redemann CT, Szoka FC Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem. 1996;7:703-714.
27. McKhann G, Drachmen D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
28. Hixson JE, Vernier DT, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res. 1990;31:545-548.
29. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
30. Toji H, Maruyama H, Sasaki K, Nakamura S, Kawakami H. Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population. Neurosci Lett. 1999;259:56-58.
31. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37:254-259.
32. Gibbs RB. Effects of estrogen on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment. Brain Res. 1997;757:10-16.
33. Gibbs RB. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol. 1998;151:289-302.
34. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology. 1997;48(suppl 7):S27-S35.
35. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 1998;18:3180-3185.
36. Okuizumi K, Takano H, Seki K, Onishi Y, Horikawa Y, Tsuji S. Genetic polymorphism of the tau gene and neurodegenerative diseases with tau pathology among Japanese (letter). Ann Neurol. 1998;44:707.
37. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease JAMA. 1997;278:1349-1356.